BIO: Bio-rad Laboratories Inc Financial Statements
Balance sheet, income statement, and cash flow statements for Bio-rad Laboratories Inc (BIO).
$9.20B Market Cap.
BIO Market Cap. (MRY)
BIO Shares Outstanding (MRY)
BIO Assets (MRY)
Total Assets
$9.36B
Total Liabilities
$2.79B
Total Investments
$6.02B
BIO Income (MRY)
Revenue
$2.57B
Net Income
-$1.84B
Operating Expense
$1.11B
BIO Cash Flow (MRY)
CF Operations
$455.20M
CF Investing
-$160.20M
CF Financing
-$218.80M
BIO Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $9,364,100,000 (-23.86%) | $12,299,070,000 (-8.91%) | $13,501,666,000 (-24.15%) | $17,799,393,000 (37.21%) |
Assets Current | $3,030,300,000 (-0.59%) | $3,048,330,000 (-3.47%) | $3,157,976,000 (58.65%) | $1,990,479,000 (-6.98%) |
Assets Non-Current | $6,333,800,000 (-31.53%) | $9,250,740,000 (-10.57%) | $10,343,690,000 (-34.57%) | $15,808,914,000 (45.94%) |
Goodwill & Intangible Assets | $704,100,000 (-4.08%) | $734,083,000 (-0.62%) | $738,635,000 (22.84%) | $601,282,000 (22.36%) |
Shareholders Equity | $6,569,300,000 (-24.85%) | $8,741,133,000 (-9.09%) | $9,615,252,000 (-29.74%) | $13,685,236,000 (38.52%) |
Property Plant & Equipment Net | $688,600,000 (-4.85%) | $723,737,000 (6.50%) | $679,564,000 (-5.15%) | $716,437,000 (3.31%) |
Cash & Equivalents | $488,100,000 (20.87%) | $403,815,000 (-7.00%) | $434,215,000 (-7.77%) | $470,783,000 (-28.91%) |
Accumulated Other Comprehensive Income | -$538,200,000 (-60.16%) | -$336,038,000 (28.02%) | -$466,822,000 (-165.92%) | -$175,553,000 (-162.15%) |
Deferred Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $50,852,000 (19.74%) |
Total Investments | $6,015,600,000 (-32.46%) | $8,906,957,000 (-12.62%) | $10,192,909,000 (-31.09%) | $14,791,701,000 (49.48%) |
Investments Current | $1,176,400,000 (-2.69%) | $1,208,887,000 (-11.24%) | $1,362,017,000 (236.55%) | $404,695,000 (20.99%) |
Investments Non-Current | $4,839,200,000 (-37.14%) | $7,698,070,000 (-12.83%) | $8,830,892,000 (-38.62%) | $14,387,006,000 (50.47%) |
Inventory | $760,000,000 (-2.63%) | $780,517,000 (8.51%) | $719,316,000 (25.70%) | $572,239,000 (-8.04%) |
Trade & Non-Trade Receivables | $452,500,000 (-7.47%) | $489,017,000 (-1.14%) | $494,645,000 (16.79%) | $423,537,000 (0.98%) |
Trade & Non-Trade Payables | $122,300,000 (-15.44%) | $144,625,000 (7.10%) | $135,041,000 (-4.86%) | $141,941,000 (1.79%) |
Accumulated Retained Earnings (Deficit) | $7,416,400,000 (-19.91%) | $9,260,629,000 (-6.44%) | $9,898,203,000 (-26.82%) | $13,525,343,000 (45.94%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $849,200,000 (-43.81%) | $1,511,254,000 (-16.18%) | $1,802,909,000 (-42.04%) | $3,110,875,000 (45.77%) |
Total Debt | $1,374,700,000 (-2.18%) | $1,405,395,000 (1.24%) | $1,388,114,000 (521.42%) | $223,376,000 (-1.03%) |
Debt Current | $42,900,000 (4.98%) | $40,865,000 (11.04%) | $36,801,000 (-0.33%) | $36,924,000 (-3.61%) |
Debt Non-Current | $1,331,800,000 (-2.40%) | $1,364,530,000 (0.98%) | $1,351,313,000 (624.75%) | $186,452,000 (-0.50%) |
Total Liabilities | $2,794,800,000 (-21.45%) | $3,557,937,000 (-8.45%) | $3,886,414,000 (-5.54%) | $4,114,157,000 (33.03%) |
Liabilities Current | $467,800,000 (-10.52%) | $522,799,000 (-8.07%) | $568,708,000 (-16.48%) | $680,938,000 (7.82%) |
Liabilities Non-Current | $2,327,000,000 (-23.33%) | $3,035,138,000 (-8.52%) | $3,317,706,000 (-3.36%) | $3,433,219,000 (39.50%) |
BIO Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $2,566,500,000 (-3.92%) | $2,671,262,000 (-4.67%) | $2,802,249,000 (-4.12%) | $2,922,545,000 (14.81%) |
Cost of Revenue | $1,187,600,000 (-4.56%) | $1,244,316,000 (0.76%) | $1,234,919,000 (-3.86%) | $1,284,449,000 (15.95%) |
Selling General & Administrative Expense | $814,000,000 (-3.29%) | $841,723,000 (1.68%) | $827,825,000 (-5.62%) | $877,122,000 (9.81%) |
Research & Development Expense | $295,900,000 (19.59%) | $247,427,000 (-3.68%) | $256,889,000 (-1.44%) | $260,638,000 (19.69%) |
Operating Expenses | $1,109,900,000 (1.91%) | $1,089,150,000 (0.41%) | $1,084,714,000 (-4.66%) | $1,137,760,000 (11.92%) |
Interest Expense | $48,900,000 (-1.09%) | $49,439,000 (29.71%) | $38,114,000 (2357.38%) | $1,551,000 (-92.91%) |
Income Tax Expense | -$498,300,000 (-134.19%) | -$212,780,000 (80.24%) | -$1,076,738,000 (-190.12%) | $1,194,798,000 (8.25%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$1,844,200,000 (-189.37%) | -$637,324,000 (82.43%) | -$3,627,535,000 (-185.27%) | $4,254,257,000 (11.54%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$1,844,200,000 (-189.37%) | -$637,324,000 (82.43%) | -$3,627,535,000 (-185.27%) | $4,254,257,000 (11.54%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$1,844,200,000 (-189.37%) | -$637,324,000 (82.43%) | -$3,627,535,000 (-185.27%) | $4,254,257,000 (11.54%) |
Weighted Average Shares | $28,214,000 (-3.41%) | $29,209,000 (-1.93%) | $29,785,000 (-0.15%) | $29,831,000 (0.21%) |
Weighted Average Shares Diluted | $28,214,000 (-3.41%) | $29,209,000 (-1.93%) | $29,785,000 (-1.40%) | $30,208,000 (0.16%) |
Earning Before Interest & Taxes (EBIT) | -$2,293,600,000 (-186.46%) | -$800,665,000 (82.84%) | -$4,666,159,000 (-185.61%) | $5,450,606,000 (10.34%) |
Gross Profit | $1,378,900,000 (-3.37%) | $1,426,946,000 (-8.96%) | $1,567,330,000 (-4.32%) | $1,638,096,000 (13.92%) |
Operating Income | $269,000,000 (-20.37%) | $337,796,000 (-30.01%) | $482,616,000 (-3.54%) | $500,336,000 (18.75%) |
BIO Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | -$160,200,000 (-892.76%) | $20,208,000 (101.67%) | -$1,207,593,000 (-51.44%) | -$797,381,000 (-1040.84%) |
Net Cash Flow from Financing | -$218,800,000 (48.60%) | -$425,647,000 (-143.72%) | $973,576,000 (1856.44%) | -$55,429,000 (89.40%) |
Net Cash Flow from Operations | $455,200,000 (21.41%) | $374,943,000 (92.83%) | $194,447,000 (-70.95%) | $669,464,000 (14.44%) |
Net Cash Flow / Change in Cash & Cash Equivalents | $85,400,000 (383.02%) | -$30,175,000 (17.53%) | -$36,589,000 (81.33%) | -$195,982,000 (-4490.28%) |
Net Cash Flow - Business Acquisitions and Disposals | -$23,400,000 (-1036.00%) | $2,500,000 (102.52%) | -$99,386,000 (20.82%) | -$125,516,000 (-48.69%) |
Net Cash Flow - Investment Acquisitions and Disposals | $28,700,000 (-83.52%) | $174,177,000 (117.52%) | -$994,211,000 (-84.74%) | -$538,171,000 (-549.97%) |
Capital Expenditure | -$165,500,000 (-5.77%) | -$156,469,000 (-38.93%) | -$112,621,000 (15.76%) | -$133,694,000 (-23.23%) |
Issuance (Repayment) of Debt Securities | -$1,000,000 (-114.13%) | -$467,000 (-100.04%) | $1,185,710,000 (39361.92%) | -$3,020,000 (99.29%) |
Issuance (Purchase) of Equity Shares | -$184,400,000 (55.05%) | -$410,244,000 (-107.07%) | -$198,119,000 (-574.65%) | -$29,366,000 (63.20%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | $9,200,000 (2766.04%) | $321,000 (-89.23%) | $2,981,000 (123.59%) | -$12,636,000 (-201.68%) |
Share Based Compensation | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Depreciation Amortization & Accretion | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
BIO Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | 53.70% (0.56%) | 53.40% (-4.47%) | 55.90% (-0.36%) | 56.10% (-0.71%) |
Profit Margin | -71.90% (-200.84%) | -23.90% (81.54%) | -129.50% (-188.94%) | 145.60% (-2.80%) |
EBITDA Margin | -89.40% (-198.00%) | -30.00% (81.98%) | -166.50% (-189.28%) | 186.50% (-3.92%) |
Return on Average Equity (ROAE) | -24.70% (-243.06%) | -7.20% (81.54%) | -39.00% (-217.47%) | 33.20% (-29.66%) |
Return on Average Assets (ROAA) | -17.50% (-243.14%) | -5.10% (81.52%) | -27.60% (-208.24%) | 25.50% (-26.93%) |
Return on Sales (ROS) | -89.40% (-198.00%) | -30.00% (81.98%) | -166.50% (-189.28%) | 186.50% (-3.92%) |
Return on Invested Capital (ROIC) | -22.20% (-236.36%) | -6.60% (82.07%) | -36.80% (-201.94%) | 36.10% (-30.71%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) |
Price to Earnings Ratio (P/E) | -5.03 (66.04%) | -14.8 (-328.55%) | -3.45 (-165.18%) | 5.3 (16.44%) |
Price to Sales Ratio (P/S) | 3.61 (2.27%) | 3.53 (-20.99%) | 4.47 (-42.05%) | 7.71 (13.13%) |
Price to Book Ratio (P/B) | 1.4 (29.99%) | 1.08 (-17.41%) | 1.3 (-21.07%) | 1.65 (-6.14%) |
Debt to Equity Ratio (D/E) | 0.42 (4.42%) | 0.41 (0.74%) | 0.4 (34.22%) | 0.3 (-3.83%) |
Earnings Per Share (EPS) | -65.36 (-199.54%) | -21.82 (82.08%) | -121.79 (-185.40%) | 142.61 (11.30%) |
Sales Per Share (SPS) | 90.97 (-0.53%) | 91.45 (-2.80%) | 94.08 (-3.97%) | 97.97 (14.56%) |
Free Cash Flow Per Share (FCFPS) | 10.27 (37.27%) | 7.48 (172.30%) | 2.75 (-84.70%) | 17.96 (12.21%) |
Book Value Per Share (BVPS) | 232.84 (-22.20%) | 299.26 (-7.30%) | 322.82 (-29.63%) | 458.76 (38.22%) |
Tangible Assets Book Value Per Share (TABVPS) | 306.94 (-22.48%) | 395.94 (-7.60%) | 428.5 (-25.67%) | 576.52 (37.50%) |
Enterprise Value Over EBIT (EV/EBIT) | -4 (69.23%) | -13 (-333.33%) | -3 (-175.00%) | 4 (33.33%) |
Enterprise Value Over EBITDA (EV/EBITDA) | -4.44 (65.71%) | -12.94 (-350.45%) | -2.87 (-171.25%) | 4.03 (15.80%) |
Asset Turnover | 0.24 (13.55%) | 0.21 (0.47%) | 0.21 (21.71%) | 0.17 (-24.89%) |
Current Ratio | 6.48 (11.10%) | 5.83 (5.01%) | 5.55 (89.98%) | 2.92 (-13.72%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | $289,700,000 (32.60%) | $218,474,000 (167.00%) | $81,826,000 (-84.73%) | $535,770,000 (12.44%) |
Enterprise Value (EV) | $10,174,917,270 (-1.77%) | $10,358,317,941 (-22.71%) | $13,401,779,424 (-39.00%) | $21,970,681,308 (27.78%) |
Earnings Before Tax (EBT) | -$2,342,500,000 (-175.55%) | -$850,104,000 (81.93%) | -$4,704,273,000 (-186.33%) | $5,449,055,000 (10.80%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$2,293,600,000 (-186.46%) | -$800,665,000 (82.84%) | -$4,666,159,000 (-185.61%) | $5,450,606,000 (10.34%) |
Invested Capital | $9,078,800,000 (-24.62%) | $12,043,768,000 (-8.40%) | $13,148,222,000 (-19.19%) | $16,269,766,000 (42.55%) |
Working Capital | $2,562,500,000 (1.46%) | $2,525,531,000 (-2.46%) | $2,589,268,000 (97.72%) | $1,309,541,000 (-13.18%) |
Tangible Asset Value | $8,660,000,000 (-25.12%) | $11,564,987,000 (-9.39%) | $12,763,031,000 (-25.79%) | $17,198,111,000 (37.79%) |
Market Capitalization | $9,197,217,270 (-2.27%) | $9,410,683,941 (-24.96%) | $12,540,748,424 (-44.52%) | $22,605,319,308 (29.99%) |
Average Equity | $7,471,770,000 (-15.50%) | $8,841,985,000 (-4.86%) | $9,293,592,500 (-27.42%) | $12,805,388,250 (58.33%) |
Average Assets | $10,566,477,750 (-15.20%) | $12,460,164,000 (-5.27%) | $13,153,988,000 (-21.24%) | $16,700,872,250 (52.61%) |
Invested Capital Average | $10,322,855,500 (-14.89%) | $12,129,020,250 (-4.46%) | $12,695,674,750 (-15.91%) | $15,097,214,500 (59.26%) |
Shares | 27,996,765 (-3.94%) | 29,145,170 (-2.28%) | 29,824,130 (-0.31%) | 29,918,233 (0.29%) |
